Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. Prasad M, et al. Among authors: karabajakian a. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917. J Immunother Cancer. 2022. PMID: 35292516 Free PMC article.
Chemotherapy for localized head and neck squamous cell cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Anticancer Drugs. 2017. PMID: 28134662 Review.
Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Anticancer Drugs. 2017. PMID: 28166090 Review.
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Karabajakian A, Bouaoud J, Michon L, Kamal M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V, Le Tourneau C, Benzerdjeb N, Fayette J, Saintigny P. Karabajakian A, et al. Oral Oncol. 2021 Aug;119:105368. doi: 10.1016/j.oraloncology.2021.105368. Epub 2021 Jun 7. Oral Oncol. 2021. PMID: 34111704 Free article.
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Foy JP, et al. Among authors: karabajakian a. Eur J Cancer. 2022 Oct;174:287-298. doi: 10.1016/j.ejca.2022.06.034. Epub 2022 Aug 26. Eur J Cancer. 2022. PMID: 36038492
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Foy JP, et al. Among authors: karabajakian a. Data Brief. 2022 Aug 27;44:108556. doi: 10.1016/j.dib.2022.108556. eCollection 2022 Oct. Data Brief. 2022. PMID: 36111282 Free PMC article.
L’immunothérapie dans les cancers ORL.
Reverdy T, Gau M, Karabajakian A, Neidhardt EM, Fayette J. Reverdy T, et al. Among authors: karabajakian a. Bull Cancer. 2018 Dec;105 Suppl 1:S35-S42. doi: 10.1016/S0007-4551(18)30388-6. Bull Cancer. 2018. PMID: 30595197 Review. French.
19 results